Predictive factors of clinical trial participant
discontinuation

Using our proprietary historical trial data, Lokavant conducted an analysis to investigate key predictive factors that increased or decreased risk of participant discontinuation in COVID-19 impacted clinical trials.

This paper explores how COVID-19 was not a leading predictor of   discontinuation risk across the trials we analyzed. Rather, what may be more impactful to a trial’s participant discontinuation risk includes a specific sponsor’s effect, trial region, and therapeutic area.

See all whitepapers
Enter your information below to download
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Lokavant makes it easy for clinical operators to run flawless trials using software and predictive analytics.